Table 1.

Study population characteristics (n = 60, total delivered cycles 302)

Age (years) median (range)	70 (43–81)
Sex (F/M)	36/24
Cancer stage (n/%)
IIIB	6/60 (10%)
IV	54/60 (90%)
Histology (n/%)
Adenocarcinoma	39/60 (65%)
Squamous cell carcinoma	17/60 (28%)
Large cell carcinoma/NOS	4/60 (7%)
Treatment (n/%)
Nivolumab	52/60 (86.7%)
2nd line	45/52 (86.5%)
3rd line	7/52 (13.5%)
Pembrolizumab*	8/60 (13.3%)

NOS not otherwise specified

*All first-line treatment for high (≥ 50%) PD-L1 tumor expression